ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky Accessibility StatementSkip NavigationAldeyra Therapeutics Touted Reproxalap's Regulatory Path While FDA Ultimately Found Insufficient EfficacyNEW YORK, March 18, 2026 /PRNewswire/ -- Investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) lost approximately 70% of their holdings afte ...

New York, New York--(Newsfile Corp. - March 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws.Throughout 2024 and 2025, Aldeyra's made forward-looking statements regarding the development and regulatory prospects of reproxalap for the treatment of dry eye disease. Management described the NDA submission and review process in terms ...

Key Takeaways Aldeyra Therapeutics received a third CRL for reproxalap's dry eye disease NDA, sending shares down 70.7%.ALDX's application failed to show substantial evidence of efficacy due to inconsistent results across studies.ALDX plans a Type A FDA meeting to clarify the steps needed for potential approval in dry eye disease.Shares of Aldeyra Therapeutics (ALDX) plunged 70.7% on Tuesday after the company announced receiving a Complete Response Letter (CRL) from the FDA for a third time for the new drug ...

Core Viewpoint - Aldeyra Therapeutics, Inc. has faced a significant decline in its stock price, dropping over 65% after receiving a Complete Response Letter from the FDA regarding its drug reproxalap for dry eye disease, indicating a failure to demonstrate efficacy in clinical trials [2]. Company Overview - Aldeyra Therapeutics, Inc. is under investigation by Block & Leviton for potential securities law violations following the FDA's response regarding reproxalap [1][4]. - The company previously disclosed that the FDA required at least one additional adequate and well-controlled study to demonstrate the drug's effectiveness [2]. Investor Information - Investors who purchased Aldeyra Therapeutics common stock and experienced a loss may be eligible to recover losses through Block & Leviton's investigation [3]. - Block & Leviton is known for representing defrauded investors and has recovered billions of dollars through litigation [7]. Legal Actions - Block & Leviton is considering filing an action to recover losses on behalf of affected investors [4]. - Whistleblowers with non-public information about Aldeyra Therapeutics are encouraged to assist in the investigation, with potential rewards for original information provided to the SEC [6].

Core Viewpoint - Aldeyra Therapeutics, Inc. experienced a significant decline in share price, falling over 65% after receiving a Complete Response Letter from the FDA regarding its drug reproxalap for dry eye disease, indicating that the application failed to demonstrate efficacy in controlled studies [2]. Group 1: Company Performance - Aldeyra Therapeutics disclosed that the FDA's Complete Response Letter stated the application "has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease" [2]. - The company had previously been informed by the FDA that the reproxalap NDA "failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes" and that further studies were required [2]. Group 2: Legal Investigation - Block & Leviton is investigating Aldeyra Therapeutics for potential securities law violations and may file an action to recover losses for investors [4]. - Investors who have lost money in Aldeyra Therapeutics are encouraged to contact Block & Leviton to learn more about their eligibility for recovery [3][5]. Group 3: Whistleblower Information - Individuals with non-public information about Aldeyra Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 4: Firm's Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Aldeyra Therapeutics following a significant stock decline after the FDA declined to approve its lead drug, reproxalap, for dry eye disease treatment [1][3]. Group 1: Investigation Details - The investigation focuses on whether Aldeyra Therapeutics' executive officers may have violated federal securities laws, potentially allowing for recovery of investor losses [1][4]. - Aldeyra Therapeutics announced on March 17, 2026, that the FDA cited insufficient evidence of efficacy for reproxalap, leading to a stock decline of over 70% in early morning trading on the same day [3]. Group 2: Company Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights, representing both individual and institutional investors in securities class action lawsuits [5]. - The firm has been recognized among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services in 2024, having recovered approximately $90.725 million for clients in cases where it served as lead or co-lead counsel [6].

Group 1 - The U.S. Food and Drug Administration (FDA) has declined to approve Aldeyra Therapeutics' drug for a specific type of eye disease [1] - This decision represents a setback for Aldeyra Therapeutics, which was seeking approval for its treatment [1] Group 2 - The FDA's rejection may impact Aldeyra's stock performance and investor sentiment [1]

Commerzbank CEO Bettina Orlopp said on Tuesday that an offer by Italy's UniCredit to buy its shares was at a very low price, underscoring the German lender's long-held reluctance about any takeov... ...

Licensing and Collaboration Agreements - Aldeyra Therapeutics has entered into an exclusive option agreement with AbbVie, granting AbbVie an option to obtain a co-exclusive license for reproxalap in the U.S. and an exclusive license outside the U.S., with an initial non-refundable payment of $1.0 million[19]. - AbbVie extended the option period by paying a $5.0 million extension fee, which will be credited against the upfront cash payment of $100.0 million upon execution of the collaboration agreement[20][22]. - Upon execution of the collaboration agreement, AbbVie will pay a $100.0 million upfront cash payment, with potential milestone payments of up to $300.0 million, including a $100.0 million milestone for FDA approval[100]. - The profit-sharing arrangement for reproxalap in the U.S. is set at 60% for AbbVie and 40% for the company, while tiered royalties will apply to net sales outside the U.S.[100]. Product Development and Clinical Trials - Aldeyra is developing multiple RASP modulators, including ADX-248 and ADX-246, targeting immune-mediated diseases, with reproxalap being the most advanced candidate[31]. - In clinical trials, reproxalap has been administered to approximately 2,700 patients and has shown a favorable safety profile with no serious adverse events reported[29]. - The Phase 1 clinical trial of ADX-629 demonstrated no treatment-related adverse events and statistically significant reductions in inflammatory markers compared to controls[38]. - ADX-629 demonstrated statistically significant reductions in psoriasis area and severity index (PASI) scores, with a peak PASI 50% responder percentage of 57% and PASI 75% responder percentage of 25% after 12 weeks of treatment[44]. - In a trial for asthma, ADX-629 led to statistically significant reductions in plasma levels of pro-inflammatory cytokines IL-5 (P=0.02) and TNFα (P<0.0001) compared to placebo[45]. - In COVID-19 patients, ADX-629 treatment resulted in a higher change from baseline in the National Institute of Allergy and Infectious Diseases Score compared to placebo, with reductions in plasma levels of cytokines CXCL9 (P=0.0008) and IFNγ (P=0.02)[46]. - In chronic cough patients, ADX-629 achieved statistical significance for reduction in awake cough frequency (P=0.01) and 24-hour cough frequency (P=0.001) compared to placebo[48]. - In atopic dermatitis, ADX-629 showed significant improvement in Eczema Area and Severity Index (EASI) scores (p=0.0006), with 50% of patients achieving EASI-50[51]. - The first chamber trial for reproxalap achieved the primary endpoint of reducing patient-reported ocular discomfort (P=0.004) relative to vehicle[57]. - The second chamber trial also achieved the primary endpoint of reducing ocular discomfort (P=0.002), supporting the activity of reproxalap[58]. - ADX-2191 showed significant improvement in best corrected visual acuity (P<0.0001) and other visual metrics in a Phase 2 trial for retinitis pigmentosa[67]. - The company plans to initiate a Phase 2/3 clinical trial of ADX-2191 in retinitis pigmentosa in the first half of 2026[68]. Regulatory Challenges and FDA Interactions - The FDA issued a Complete Response Letter for reproxalap, stating that the NDA did not demonstrate efficacy in treating ocular symptoms associated with dry eyes, requiring at least one additional study[55]. - The FDA has assigned a PDUFA date of March 16, 2026, for the resubmission of the reproxalap NDA, which includes results from additional clinical trials[171]. - The FDA may extend the review process for an additional three months to consider further information or clarifications[128]. - The FDA can require a Risk Evaluation and Mitigation Strategy (REMS) for certain products to ensure their benefits outweigh risks, which may include prescribing restrictions and post-marketing studies[122][137]. - The FDA may withdraw product approval if ongoing regulatory requirements are not met or if new safety findings arise post-market[131]. - The FDA's review process may involve multiple centers if the product is deemed a combination product, potentially complicating the review[128]. - The FDA may issue a Complete Response Letter (CRL) outlining deficiencies in an NDA submission, requiring substantial additional testing or information for reconsideration[130]. - The FDA approval process requires extensive testing and compliance with regulations, which can significantly impact the timeline for bringing new products to market[115]. Financial Overview and Funding Needs - Aldeyra has no products approved for sale and has primarily funded operations through equity sales and debt, indicating a need for additional capital to support product development[25]. - The company has incurred significant operating losses since inception and anticipates continued losses over the next several years, raising concerns about future profitability[166]. - If the AbbVie Option is not exercised, the company may struggle to raise additional capital needed for the development and commercialization of reproxalap[176]. - The company recognizes research and development expenses as incurred, with costs influenced by various factors including clinical trial design and patient enrollment rates[156][162]. - Research and development expenses totaled $25.7 million for the year ended December 31, 2025, compared to $48.2 million for the year ended December 31, 2024[154]. Market and Competitive Landscape - The competitive landscape includes large pharmaceutical companies with greater resources and experience, posing challenges for market acceptance of new products[81]. - The company anticipates intense competition as new products enter the market, which may affect the commercial success of its product candidates[80]. - The success of reproxalap's commercialization is contingent upon achieving adequate market acceptance and securing reimbursement from third-party payors[169]. - The company faces competition from other pharmaceutical products that may be approved more quickly or marketed more effectively, which could reduce its commercial opportunities[166]. - Allergic conjunctivitis affects over 1 billion people globally, with no FDA-approved products for chronic treatment of both dry eye disease and allergic conjunctivitis[77]. Research and Development Strategy - The company plans to continue expanding its product candidate pipeline through licensing or acquiring new immune-modulating approaches[24]. - The company is heavily reliant on the successful commercialization of reproxalap, with significant risks associated with obtaining FDA marketing approval and potential delays in commercialization[165]. - The company plans to evaluate the development and commercialization of therapies for immune-mediated diseases, potentially in-licensing or acquiring new product candidates[181]. - The company may not successfully identify or develop additional product candidates, impacting its pipeline and market potential[194]. - The company is developing novel product candidates for immune-mediated diseases, facing challenges due to the lack of historical clinical trial experience and regulatory pathways that are not well defined[199]. Operational and Organizational Aspects - The company does not own manufacturing facilities and relies on third-party contract manufacturers for all required materials and products[110]. - As of December 31, 2025, the company had 8 full-time employees and engaged several consultants, with no labor union representation[111]. - The company emphasizes the importance of attracting and retaining talent, aiming to create an equitable and inclusive work environment[112]. - The company is subject to various regulatory requirements, including compliance with cGMP regulations, which could impact manufacturing and operational capabilities[152]. Legislative and Regulatory Environment - The Inflation Reduction Act of 2022 allows the HHS to negotiate prices for certain high-expenditure drugs under Medicare, with provisions beginning to take effect in fiscal year 2023[141]. - The Affordable Care Act expanded coverage for the uninsured and increased industry rebates for drugs under Medicaid programs, impacting the biopharmaceutical industry significantly[138]. - Legislative and regulatory changes could significantly impact pharmaceutical companies, including pricing controls and reimbursement constraints at both federal and state levels[144][145]. - The current administration's policies may lead to reduced drug prices and increased operational costs for manufacturers due to new pricing agreements and regulations[143].

Aldeyra Therapeutics FY Conference Summary Company Overview - **Company**: Aldeyra Therapeutics (NasdaqCM: ALDX) - **Focus**: Development of pharmaceuticals targeting immune-mediated diseases through RASP modulators - **Key Products**: - Reproxalap: Treatment for dry eye disease and allergic conjunctivitis - ADX-2191: Novel formulation for primary vitreoretinal lymphoma and retinitis pigmentosa - ADX-248 and ADX-246: Oral treatments for atopic dermatitis and other conditions Key Points and Arguments Regulatory Updates - **PDUFA Date**: Extended to March 16, 2026, for reproxalap's approval for dry eye disease [2][4] - **Regulatory History**: - Received a Complete Response Letter (CRL) in 2023 due to a missed co-primary endpoint [4] - A second CRL was issued for a baseline imbalance, which is considered unique [5] - Resubmitted NDA with additional trial data, leading to the current PDUFA extension [6][7] Market Positioning - **Reproxalap's Differentiation**: - Potential to be the only drug with a rapid onset of action (minutes) for dry eye treatment [10][11] - Unique ability to control redness, which is significant for patient satisfaction [12] - **Allergic Conjunctivitis**: - Completed two positive Phase 3 trials, with plans for a supplemental NDA following dry eye approval [13][14] Partnership with AbbVie - **Terms of Agreement**: - AbbVie has an option to market reproxalap, with a $200 million potential payout upon approval [19][20] - Revenue split post-approval: 60% to AbbVie, 40% to Aldeyra [20] - **Collaboration**: Ongoing partnership for both dry eye and allergic conjunctivitis indications [18] Pipeline and Future Developments - **Upcoming Milestones**: - Focus on allergic conjunctivitis following dry eye approval [21] - Plans for NDA submission for ocular lymphoma (primary vitreoretinal lymphoma) [22] - **ADX-248 for Atopic Dermatitis**: - Positioned as a more potent oral treatment, currently in Phase 1 trials [26][27] Financial Outlook - **Cash Position**: - Reported $75 million in cash as of Q3, providing approximately two years of runway [28] - Budget allocation includes reserves for potential dry eye trials and support for ongoing programs [28][29] Additional Insights - **Market Landscape**: The dry eye treatment market is expanding, with various new agents being introduced, but none offering the rapid relief that reproxalap promises [9][10] - **Patient Considerations**: Emphasis on the importance of both efficacy and cosmetic outcomes for patients suffering from dry eye and allergic conjunctivitis [11][12] This summary encapsulates the critical aspects of Aldeyra Therapeutics' recent conference, highlighting the company's strategic positioning, regulatory challenges, and future opportunities in the biotechnology sector.